Upregulation of vimentin and aberrant expression of E-cadherin/Β- catenin complex in oral squamous cell carcinomas: Correlation with the clinicopathological features and patient outcome

Modern Pathology

Volumn 23, Issue 2, 2010, Pages 213-224

  Liu, Lai Kui ^a   Jiang, Xiao Yun ^a   Zhou, Xiang Xiang ^a   Wang, Dong Miao ^a   Song, Xiao Ling ^a   Jiang, Hong Bing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Oral squamous cell carcinoma; Vimentin

Indexed keywords

BETA CATENIN; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; UPREGULATION;

ADULT; AGED; BETA CATENIN; CADHERINS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VIMENTIN;

EID: 76349117690     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.160     Document Type: Article

References (57)

1. Forastiere AA, Ang K, Brizel D, et al. Head and neck cancers. J Natl Compr Canc Netw 2005;3:316-391.
2. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005;5:127-135.
3. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent 2001;49:72-82.
4. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993;328:184-194.
5. Bettendorf O, Piffkò J, Bànkfalvi A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 2004;40:110-119.
6. Bryne M, Koppang HS, Lilleng R, et al. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 1992;166:375-381.
7. Woolgar JA. Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. Oral Oncol 2006;42:229-239.
8. Mandal M, Myers JN, Lippman SM, et al. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008;112:2088-2100.
9. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005;17:548-558.
10. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006;66:8319-8326.
11. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-746.
12. Nawshad A, LaGamba D, Polad A, et al. Trans form ing growth factor-b Signaling during epithelial-mesenchy-mal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 2005;179:11-23.
13. Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev 1999;18:15-30.
14. Hsu YM, Chen YF, Chou ChY, et al. KCl cotransporter-3 down-regulates E-cadherin/b-catenin complex to promote epithelial-mesenchymal transition. Cancer Res 2007;67:11064-11073.
15. Zheng Z, Pan J, Chu B, et al. Downregulation and abnormal expression of E-cadherin and b-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol 1999;30:458-466.
16. Pyo SW, Hashimoto M, Kim YS, et al. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome. J Craniomaxillofac Surg 2007;35:1-9.
17. Chang HW, Chow V, Lam KY, et al. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 2002;94:386-392.
18. Diniz-Freitas M, García-Caballero T, Antúnez-López J, et al. Reduced E-cadherin expression is an indicator of unfavourable prognosis in oral squamous cell carcinoma. Oral Oncol 2006;42:190-200.
19. Mahomed F, Altini M, Meer S. Altered E-cadherin/ b-catenin expression in oral squamous carcinoma with and without nodal metastasis. Oral Dis 2007;13: 386-392.
20. Tanaka N, Odajima T, Ogi K, et al. Expression of E-caderin, a-catenine, and b-cetenin in the process of lymph node metastasis in oral squamous cell carcinoma. Br J Cancer 2003;89:557-563.
21. Andrews NA, Jones AS, Helliwell TR, et al. Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases. Br J Cancer 1997;75:1474-1480.
22. Chow V, Yuen AP, Lam KY, et al. A comparative study of the clinicopathological significance of E-cadherin and catenins (a,b,g) expression in the surgical management of oral tongue carcinomas. J Cancer Res Clin Oncol 2001;127:59-63.
23. Bánkfalvi A, Krassort M, Végh A, et al. Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med 2002;31:450-457.
24. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-1455.
25. Behrens J, von Kries JP, Kühl M, et al. Functional interaction of b-catenin with the transcription factor LEF-1. Nature 1996;382:638-642.
26. Conacci-Sorrell M, Zhurinsky J, Ben Ze'ev A. The cadherin-catenin adhesion system in signaling and cancer. J Clin Invest 2002;109:987-991.
27. Steinert PM, Roop DR. Molecular and cellular biology of intermediate filaments. Annu Rev Biochem 1988;57:593-625.
28. Ramaekers FC, Haag D, Kant A, et al. Coexpression of keratin-and vimentin-type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci USA 1983;80:2618-2622.
29. Gilles C, Polette M, Piette J, et al. Vimentin expression in cervical carcinomas: association with invasive and migratory potential. J Pathol 1996;180:175-180.
30. Gilles C, Polette M, Zahm JM, et al. Vimentin contributes to human mammary epithelial cell migration. J Cell Sci 1999;112:4615-4625.
31. Paccione RJ, Miyazaki H, Patel V, et al. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol Cancer Ther 2008;7:2894-2903.
32. Gilles C, Polette M, Mestdagt Me, et al. Transactivation of vimentin by b-catenin in human breast cancer cells. Cancer Res 2003;63:2658-2664.
33. Bryne M, Boysen M, Alfsen CG, et al. The invasive front of carcinomas. The most important area for tumor prognosis? Anticancer Res 1998;18:4757-4764. (Pubitemid 29042056)
34. Bànkfalvi A, Piffkò J. Prognostic and predictive factors in oral cancer: the role of the invasive tumor front. J Oral Pathol Med 2000;29:291-298.
35. Bryne M, Koppang HS, Lilleng R, et al. New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J Oral Pathol Med 1989;18:432-437.
36. Bryne M, Jenssen N, Boysen M. Histological grading in the deep invasive front of T1 and T2 glottic squamous cell carcinomas has high prognostic value. Virchows Arch 1995;427:277-281.
37. Chui X, Egami H, Yamashita J, et al. Immunohisto-chemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996;73:1233-1236.
38. Engels K, Knauer SK, Metzler D, et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 2007;211:532-540.
39. Kokkinos MI, Wafai R, Wong MK, et al. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs 2007;185:191-203.
40. Islam S, Kim JB, Trendel J, et al. Vimentin expression in human squamous carcinoma cells: relationship with phenotypic changes and cadherin-based cell adhesion. J Cell Biochem 2000;78:141-150.
41. Bindels S, Mestdagt M, Vandewalle C, et al. Regulation of vimentin by SIP1 in human epithelial breast tumor cells. Oncogene 2006;25:4975-4985.
42. Sasahira T, Kirita T, Bhawal UK, et al. Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squa-mous cell carcinoma. Histopathology 2007;51:166-172. (Pubitemid 47083983)
43. Keski-Säntti H, Atula T, Tikka J, et al. Predictive value of histopathologic parameters in early squamous cell carcinoma of oral tongue. Oral Oncol 2007;43:1007-1013.
44. de Vicentel JC, Lequerica-Fernández P, Santamar?́a J, et al. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med 2007;36:415-424.
45. Lin PY, Yu ChH, Wang JT, et al. Expression of hypoxia-inducible factor-1a is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 2008;37:18-25.
46. Yanamoto S, Kawasaki G, Yoshitomi I, et al. Clinico-pathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 2007;43:869-877.
47. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al. Oral squamous cell carcinoma histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005;29:167-178.
48. de Aguiar Jr AF, Kowalski LP, de Almeida OP. Clinicopathological and immunohistochemical evaluation of oral squamous cell carcinoma in patients with early local recurrence. Oral Oncol 2007;43:593-601.
49. Ginos MA, Page GP, Michalowicz BS, et al. Identification of a gene expression signature associate with recurrent disease in squamous cell carcinoma of head and neck. Cancer Res 2004;64:55-63.
50. de Araujo VC, Pinto Júnior DS, de Sousa SO, et al. Vimentin in oral squamous cell carcinoma. Eur Arch Otorhinolaryngol 1993;250:105-109.
51. Wang X, Zhang J, Fan M, et al. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:547-554.
52. Bánkfalvi A, Krassort M, Buchwalow IB, et al. Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression. J Pathol 2002;198:343-351.
53. Ueda G, Sunakawa H, Nakamori K, et al. Aberrant expression of beta and gamma-catenin is an independent prognostic marker in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2006;35:356-361.
54. Foschini MP, Cocchi R, Morandi L, et al. E-Cadherin loss and DNP73L expression in oral squamous cell carcinomas showing aggressive behavior. Head Neck 2008;30:1475-1482.
55. Kurtz KA, Hoffman HT, Zimmerman MB, et al. Decreased E-cadherin but not b-catenin expressionis associated with vascular invasion and decreased survival in head and neck squamous carcinomas. Otolaryngol Head Neck Surg 2006;134:142-146.
56. Pukkila MJ, Virtaniem JA, Kumpulainen EJ, et al. Nuclear b-catenin is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol 2001;54:42-47.
57. de Castro J, Gamallo C, Palacios J, et al. b-Catenin expression pattern in primary esophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. Virchows Arch 2000;437:599-604.